ZW25 (Zanidatamab) + Capecitabine + Cisplatin + Fluorouracil + Leucovorin + Oxaliplatin + Bevacizumab + Gemcitabine
Phase 2CompletedDevelopment Stage
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
Aug 29, 2019 → Aug 30, 2025
About ZW25 (Zanidatamab) + Capecitabine + Cisplatin + Fluorouracil + Leucovorin + Oxaliplatin + Bevacizumab + Gemcitabine
ZW25 (Zanidatamab) + Capecitabine + Cisplatin + Fluorouracil + Leucovorin + Oxaliplatin + Bevacizumab + Gemcitabine is a phase 2 stage product being developed by Jazz Pharmaceuticals for HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03929666. Target conditions include HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer.
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03929666 | Phase 2 | Completed |
Competing Products
6 competing products in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| SHR-4602 | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| SHR-A1811 combined with Pyrotinib. + SHR-A1811 combined with other antitumor therapies | Jiangsu Hengrui Medicine | Phase 1/2 | 41 |
| VIR-5818 + pembrolizumab | Merck | Phase 1/2 | 41 |
| Zanidatamab + Evorpacept | Jazz Pharmaceuticals | Phase 1/2 | 38 |
| ZW25 (Zanidatamab) + Paclitaxel + Capecitabine + Vinorelbine + Tucatinib + Tucatinib | Jazz Pharmaceuticals | Phase 1 | 30 |
| ZW49 | Zymeworks | Phase 1 | 28 |